NCT06104319 - Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

September 23, 2025

Study Completion Date

September 23, 2025

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

DRUG

GSK4532990

GSK4532990 will be administered

Trial Locations (14)

GSK Investigational Site, Miami Lakes

GSK Investigational Site, Miami

GSK Investigational Site, Miami

GSK Investigational Site, Brandon

GSK Investigational Site, Indianapolis

GSK Investigational Site, El Dorado

GSK Investigational Site, Marrero

GSK Investigational Site, San Antonio

GSK Investigational Site, San Antonio

GSK Investigational Site, Austin

GSK Investigational Site, Montclair

GSK Investigational Site, Chula Vista

GSK Investigational Site, San Diego

GSK Investigational Site, San Diego